Comparably Awards

Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Powered by our proprietary REMaster technology platform, we can now create medicines with the unique ability to alter the way genes are read from the genome, correcting dysregulation or eliminating the gene message altogether. These are innovative therapeutic solutions with the potential to address disease drivers at their origin. read more

This company is accepting feedback from verified employees EMPLOYEE PARTICIPANTS: 35

TOTAL RATINGS: 958

CEO: Pete Smith

Pete Smith Remix Therapeutics CEO Rating

Remix Therapeutics' CEO, Pete Smith, has 35 employee ratings and a score of 91/100, placing them in the Top 5% of similar size companies on Comparably with 51-200 Employees and Top 5% of other companies in Boston. When breaking the CEO score down by factors such as department, gender, and ethnicity, we see that males at Remix Therapeutics rate Pete Smith higher than females, giving the CEO a score of 91/100.

Last updated months ago.

Where This Score Ranks Remix Therapeutics' CEO Rating

TOP
5%
In the Top 5% of 2035 Similar Sized Companies on Comparably
TOP
5%
In the Top 5% of 270 Nearby Companies in Boston
1st
1st place versus 3 competitors rated on Comparably

Jan

Feb

Mar

A+91 / 100

Jan

Remix Therapeutics CEO Pete Smith Bio

Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Pete received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.

Who Ranks Remix Therapeutics' CEO Rating the Highest?

Department - Biomolecular Sciences and Lead Discovery 93/100

Department - Chemistry 92/100

Ethnicity - Caucasian 92/100

Who Ranks Remix Therapeutics' CEO Rating the Lowest?

Department - Discovery Biology 86/100

Gender - Female 89/100

Department - Bioinformatics and Data Science 90/100

Remix Therapeutics CEO Pete Smith At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Remix Therapeutics.

Based on 35 ratings, Pete Smith ranks right above Novartis Pharmaceuticals' CEO, Vas Narasimhan.

Remix Therapeutics' CEO is highly regarded by the Biomolecular Sciences and Lead Discovery department, the Chemistry department, and Caucasian employees. However, the Discovery Biology department, Female employees, and the Bioinformatics and Data Science department have a less favorable view of the CEO and believe there is room for improvement. Overall, the CEO score has remained stable over the last 90 days.